Advertisement

Annals of Surgical Oncology

, Volume 10, Issue 10, pp 1176–1183 | Cite as

Patterns and Predictors of Failure after Curative Resections of Carcinoma of the Ampulla of Vater

  • Takeshi TodorokiEmail author
  • Naoto Koike
  • Yukio Morishita
  • Toru Kawamoto
  • Nobuhiro Ohkohchi
  • Junichi Shoda
  • Yoshiharu Fukuda
  • Hideto Takahashi
Original Articles

Abstract

Background:Curative resection does not always equate with long-term survival. The aim was to identify patterns and predictors of failure and independent factors of prognosis after curative resection.

Methods:Sixty-six patients with ampullary carcinoma who underwent surgical intervention were reviewed. Fifty-nine patients underwent pancreaticoduodenectomy. Cox regression analysis, log-rank test, Fisher exact test, or χ2 test was used.

Results:No patient died as a result of surgery; major complications occurred in three, and the 5-year survival rate after curative resection (n = 55) was 52.6%. Significant survival predictors were preoperative serum carcinoembryonic antigen level; gross tumor appearance; tumor, node, and tumor node metastasis stage; and microscopic lymphatic vessel and venous invasion in the primary tumor. Multivariate analysis demonstrated that lymphatic vessel invasion, tumor, and tumor node metastasis stage were significant independent prognostic factors. No patient experienced locoregional failure alone; all 24 relapsed patients had distant failure, and six of them had both. The liver was the most frequent metastatic organ, followed by nodes, peritoneum, lung, and bone. The carcinoembryonic antigen and carbohydrate antigen levels and lymphatic vessel and venous invasion were significant predictors of distant failure, and the mean time to relapse was 13 (range, 0.7–33) months.

Conclusions:Curative resection is associated with significant survival; however, effective systemic adjuvant therapy is needed to prevent distant failure for patients with elevated carcinoembryonic antigen and carbohydrate antigen levels or positive lymphatic vessel or venous invasion. A 3-year follow-up period would be necessary to document relapses.

Key Words

Ampullary carcinoma Carcinoma of the papilla of Vater Curative resection Patterns of failure Predictors of metastasis Prognostic factors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Beger HG, Treitschke F, Gansauge F, Harada N, Hiki N, Mattfeldt T. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg 1999; 134: 526–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF. Factors predictive of survival in ampullary carcinoma. Ann Surg 1998; 228: 87–94.PubMedCrossRefGoogle Scholar
  3. 3.
    Bottger TC, Boddin J, Heintz A, Junginger T. Clinicopathologic study for the assessment of resection for ampullary carcinoma. World J Surg 1997; 21: 379–83.PubMedCrossRefGoogle Scholar
  4. 4.
    Talamini MA, Moesinger RC, Pitt HA, et al. Adenocarcinoma of the ampulla of Vater: a 28-year experience. Ann Surg 1997; 225: 590–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Roder JD, Schneider PM, Stein HJ, Siewert JR. Number of lymph node metastases is significantly associated with survival in patients with radically resected carcinoma of the ampulla of Vater [see comments]. Br J Surg 1995; 82: 1693–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Delcore R Jr, Connor CS, Thomas JH, Friesen SR, Hermreck AS. Significance of tumor spread in adenocarcinoma of the ampulla of Vater. Am J Surg 1989; 158: 593–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Fleming ID, Cooper JS, Henson DE, et al., eds. AJCC Cancer Staging Manual. 5th ed. Philadelphia, New York: Lippincott-Raven, 1997.Google Scholar
  8. 8.
    Nakao A. Pancreatic head resection with segmental duodenectomy and preservation of the gastroduodenal artery. Hepatogastroenterology 1998; 45: 533–5.PubMedGoogle Scholar
  9. 9.
    Akaike H. Information theory and extension of the maximum likelihood principle. In: Csaki BFP, ed. Second International Symposium on Information Theory. Budapest: Akademiai Kiado, 1973: 267–81.Google Scholar
  10. 10.
    Nakao A, Harada A, Nonami T, et al. Prognosis of cancer of the duodenal papilla of Vater in relation to clinicopathological tumor extension. Hepatogastroenterology 1994; 41: 73–8.PubMedGoogle Scholar
  11. 11.
    Dorandeu A, Raoul JL, Siriser F, et al. Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases. Gut 1997; 40: 350–5.PubMedGoogle Scholar
  12. 12.
    Kopelson G. Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: the role of adjuvant pre or postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1983; 9: 911–5.PubMedGoogle Scholar
  13. 13.
    Yamaguchi K, Nagai E, Ueki T, Nishihara K, Tamaka M. Carcinoma of the ampulla of Vater. Aust N Z J Surg 1993; 63: 256–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Kayahara M, Nagakawa T, Ohta T, Kitagawa H, Miyazaki I. Surgical strategy for carcinoma of the papilla of Vater on the basis of lymphatic spread and mode of recurrence. Surgery 1997; 121: 611–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Willett CG, Warshaw AL, Convery K, Compton CC. Patterns of failure after pancreaticoduodenectomy for ampullary carcinoma. Surg Gynecol Obstet 1993; 176: 33–8.PubMedGoogle Scholar
  16. 16.
    Splinter TA, Obertop H, Kok TC, Jeekel J. Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas: a non-randomized pilot study. J Cancer Res Clin Oncol 1989; 115: 200–2.PubMedCrossRefGoogle Scholar
  17. 17.
    Hoffman JP, Cooper HS, Young NA, Pendurthi TK. Preoperative chemotherapy of chemoradiotherapy for the treatment of adenocarcinoma of the pancreas and ampulla of Vater. J Hepatobiliary Pancreat Surg 1998; 5: 251–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776–782.PubMedCrossRefGoogle Scholar
  19. 19.
    Abrams RA, Grochow LB, Chakravarthy A, et al. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19–9 levels. Int J Radiat Oncol Biol Phys 1999; 44: 1039–46.PubMedGoogle Scholar
  20. 20.
    Neoptolemos JP, Talbot IC, Shaw DC, Carr-Locke DL. Long-term survival after resection of ampullary carcinoma is associated independently with tumor grade and a new staging classification that assesses local invasiveness. Cancer 1988; 61: 1403–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Monson JR, Donohue JH, McEntee GP, et al. Radical resection for carcinoma of the ampulla of Vater. Arch Surg 1991; 126: 353–7.PubMedGoogle Scholar
  22. 22.
    Klempnauer J, Ridder GJ, Pichlmayr R. Prognostic factors after resection of ampullary carcinoma: multivariate survival analysis in comparison with ductal cancer of the pancreatic head. Br J Surg 1995; 82: 1686–91.PubMedCrossRefGoogle Scholar
  23. 23.
    Allema JH, Reinders ME, van Gulik TM, et al. Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. Surgery 1995; 117: 247–53.PubMedCrossRefGoogle Scholar
  24. 24.
    Farrell RJ, Noonan N, Khan IM, Goggins M, Kelleher DP, Keeling PW. Carcinoma of the ampulla of Vater: a tumour with a poor prognosis? Eur J Gastroenterol Hepatol 1996; 8: 139–44.PubMedCrossRefGoogle Scholar
  25. 25.
    Su CH, Shyr YM, Lui WY, P’eng FK. Factors affecting morbidity, mortality and survival after pancreaticoduodenectomy for carcinoma of the ampulla of Vater. Hepatogastroenterology 1999; 46: 1973–9.PubMedGoogle Scholar
  26. 26.
    Futakawa N, Kimura W, Wada Y, Muto T. Clinicopathological characteristics and surgical procedures for carcinoma of the papilla of Vater. Hepatogastroenterology 1996; 43: 260–7.PubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2003

Authors and Affiliations

  • Takeshi Todoroki
    • 1
    • 6
    Email author
  • Naoto Koike
    • 1
  • Yukio Morishita
    • 2
  • Toru Kawamoto
    • 1
  • Nobuhiro Ohkohchi
    • 1
  • Junichi Shoda
    • 3
  • Yoshiharu Fukuda
    • 5
  • Hideto Takahashi
    • 4
  1. 1.Department of SurgeryHitachi Mito General HospitalHitachiJapan
  2. 2.Department of PathologyHitachi Mito General HospitalHitachiJapan
  3. 3.Department of Internal MedicineHitachi Mito General HospitalHitachiJapan
  4. 4.Institute of Clinical Medicine and Department of Epidemiology and BiostatisticsHitachi Mito General HospitalHitachiJapan
  5. 5.Institute of Community of MedicineUniversity of TsukubaTsukuba-Shi
  6. 6.Department of SurgeryInstitute of Clinical Medicine, University of TsukubaTsukuba-ShiJapan

Personalised recommendations